StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ALMSBullishIndustry Newsnews
High materiality8/10

Alumis' Envudeucitinib data reinforce 4Q2026 psoriasis NDA timing

Oct 9, 2026, 7:17 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive efficacy signals, best-in-class 54% PASI100, durable scalp/itch outcomes, and a firm 4Q2026 NDA timeline create near-term catalysts with potential for multiple expansion if regulatory risk remains manageable.

AI summary

What happened, with direct paths to the underlying reporting

Alumis reports strong ONWARD Phase 3 data for envudeucitinib, including a 54% PASI 100 response at Week 48—the highest among oral psoriasis therapies. Durable scalp clearance, itch relief, and quality-of-life gains support its competitive profile, with NDA submission planned for 4Q2026. Positive safety signals through ONWARD3 further bolster near-term regulatory optimism.

  • Envudeucitinib hits 54% PASI 100 at Week 48; top among oral psoriasis therapies.
  • ONWARD3 shows durable scalp clearance and rapid itch relief across patients.
  • NDA submission for moderate-to-severe plaque psoriasis planned in 4Q2026.
  • Long-term safety remains favorable with no new signals through ONWARD3.
  • ONWARD program enrolled >1,700 patients across ONWARD1/2/3.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event